Sweden has revised a planned update to the general guidelines for medicines reimbursement and pricing, limiting the immediate change to how high-budget-impact medicines are assessed. The Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV) still intends to consider large expected or realised expenditure when assessing whether a reimbursed price is reasonable, but it will not now introduce a fixed method linking rising expenditure to recurring price reductions.
TLV consulted in December 2025 on new general guidelines. That draft proposed a more systematic method under which the accepted price of a medicine could be reduced as the product reached higher sales-value levels. In access terms, that would have linked price erosion more directly to absolute budget impact.
In its 27 April update, TLV said it was not abandoning budget impact as a pricing consideration. It is instead withdrawing the more mechanical element of the December proposal. High expected or realised expenditure may still affect TLV’s view of whether the reimbursed price is reasonable, but price reductions will not follow automatically from a medicine crossing defined sales-value thresholds.
TLV linked the adjustment to two wider pricing constraints. First, it said the conditions for companies to offer confidential prices during TLV case handling need to be strengthened. The proposed reduction model could otherwise require public price cuts larger than companies would normally accept. Second, TLV pointed to uncertainty in international pharmaceutical pricing, including the US debate on the Most Favored Nation principle and the possible effects of external price-linking on Swedish prices and supply.
TLV plans to decide on the general guidelines on 11 June 2026. They are due to enter into force on 1 October 2026. The revised approach keeps high-budget-impact products within TLV’s price scrutiny, but avoids a pre-set downward price path while confidential-pricing arrangements and international pricing risks remain unsettled.
Source: Dental and Pharmaceutical Benefits Agency, TLV
Link: Justerad metod och tidplan i riktlinje för subvention och prissättning av läkemedel (Adjusted method and timetable in guideline for reimbursement and pricing of medicines)
Date: 27 April 2026
